Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 9/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SAT1 | P21673 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24909981 | 0.90 | LPAR3 (0.41) | LPAR3LPAR2LPAR1CYP3A4SAT1 | |
| SCHEMBL483082 | 0.81 | — | — | |
| SCHEMBL2523093 | 0.80 | LPAR3 (0.43) | LPAR3LPAR2LPAR1ALDH1A1CYP3A4 | |
| SCHEMBL2048484 | 0.80 | LPAR3 (0.60) | LPAR3LPAR2LPAR1ALDH1A1CYP3A4 | |
| SCHEMBL5965100 | 0.79 | LPAR3 (0.65) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL24909869 | 0.79 | LPAR3 (0.33) | LPAR3LPAR2LPAR1ALDH1A1 | |
| SCHEMBL12254989 | 0.78 | SAT1 (0.52) | LPAR3LPAR2LPAR1ALDH1A1CYP3A4 | |
| SCHEMBL15729175 | 0.78 | SAT1 (0.52) | LPAR3LPAR2LPAR1ALDH1A1CYP3A4 | |
| SCHEMBL11698797 | 0.77 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL11699989 | 0.77 | LPAR3 (0.69) | LPAR3LPAR2LPAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027214-A1 | Modulation of immunostimulatory activity of immunostimulatory Oligonucleotide analogs by positional chemical changes | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027214-A1 | Modulation of immunostimulatory activity of immunostimulatory Oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | LPAR3 87/4885LPAR2 95/4885LPAR1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.